Focus Sectors
Life Sciences
Why Switzerland for life sciences
The Swiss life sciences industry has been one of the world leaders for decades.
The pharma and medtech ecosystems cover the entire value chain and include universities and research institutes, large Swiss and foreign companies, start-ups and medium-sized businesses, suppliers and service providers, investors and advisors, support organisations and foundations, and, last but not least, clinics.
The individual organisations and companies are consistently among the world’s top performers. This creates optimal conditions for start-ups: they are able to focus on their core innovation and rely on the ecosystem for all other tasks. And the talent pool of tens of thousands of experienced and highly qualified people is of great benefit to young start-ups in particular.
Data-based insights
Multi-billion dollar exits
The most spectacular exits in Switzerland are made by healthcare start-ups. The record is held by Basel-based biotech company Actelion, which was acquired by Johnson & Johnson in 2017 for USD 30 billion US in cash. A few years earlier, Swiss medtech company Synthes was sold for USD 21 billion.
Although such figures are not reached every year, there is a steady stream of large exits: In 2023, VectivBio was acquired by Ironwood Pharmaceuticals for USD 1 billion and Boehringer Ingelheim acquired T3 Pharma for an amount of up to CHF 500 million. And Swiss start-ups are also in demand in the medtech sector: in 2024, Bruker Corporation took over Chemspeed Technologies, which manufactures laboratory automation solutions, and dental technology group Straumann bought Mininavident, manufacturer of the world’s smallest dynamic navigation system for dental implants.
Tens of thousands of skilled workers
Employee numbers have developed extremely dynamically over the last 10 years. Between 2014 and 2023, both the medtech sector and the biotech sector increased by 35%, demonstrating the success of Swiss companies on the global market.
It also shows clearly that companies are able to attract bright minds from all over the world. Switzerland not only offers an optimal environment for life sciences companies, but is also attractive to employees. It is not surprising that in this country 44% of all employees and 50% of all start-up founders have a foreign passport.
Investment and private investors
Research-intensive life sciences start-ups rely on large sums of money for product development. In the five years from 2020 to 2024, more than CHF 5 billion in venture capital was invested in Swiss start-ups in the biotech and life sciences industry.
The money often comes from private assets. For Swiss VCs, ultra-high-net-worth individuals – UHNWIs – and family offices are the most important financial backers. Private foundations and individuals ensure improvements in the ecosystem through donations and investments.
The sums can be enormous: in 2024, Fondation Botnar donated USD 1 billion for a new immunology research institute in Basel. Over the next 15 years, this money will be used to set up the Botnar Institute for Immune Engineering (BIIE), and for research into cost-effective immunotherapies.
Recently Caught Our Attention in Life Sciences
Start-ups
Investors
Success Stories
-
Read more: Fajer Mushtaq, Clean Tech Entrepreneur
Fajer Mushtaq, co-founder and CEO of Oxyle, has raised about CHF 9 million in non-dilutive funds in recent years from innovation programmes, the public sector…
-
Read more: Andreas Brenner, Serial Entrepeneur
Andreas Brenner started at the age of 28, when he founded Avrios.com. He spent seven years as CEO responsible for building an SaaS platform that…
-
Read more: Switzerland, Big Pharma’s Shopping Centre
The top pharmaceutical companies are very active in Switzerland, participating in large financing rounds and acquiring companies or drug candidates. In 2024, the global number…
News for
Life Sciences
-
CHF 2.4 billion for Swiss start-ups
Investment in knowledge-based start-ups fell again in 2024, by 8.5% compared with the previous year. The number of financing rounds also fell for the first…
startupticker.ch
-
Frank Thelen invests in Akina’s CHF 2.8 million seed round
Through its investment in Akina, Freigeist Capital, the Deep Tech VC founded by Frank Thelen, has led its first investment in the healthtech sector. The…
startupticker.ch
-
RhyGaze raises USD 86 million to advance gene therapy for retinal diseases
Based in Basel and Philadelphia, USA, RhyGaze has secured a Series A financing of USD 86 million to enable clinical advancements for its lead candidate,…
startupticker.ch
-
Windward Bio launches with $200 million Series A financing round
Founded by serial entrepreneur Luca Santarelli, Windward Bio has just launched with a $200 million capital injection. These funds will accelerate clinical advancements in programs…
startupticker.ch
-
Numab raises additional CHF50 million
Numab Therapeutics, a clinical stage biotechnology company focusing on multi-specific antibodies in immunology and oncology, closed an oversubscribed CHF 50 million Series C extension, bringing…
startupticker.ch
-
CeQur secures $120 million to scale diabetes management solutions
With more than 6000 patients using the injection-free insulin delivery device, CeQur Simplicity patch, Medtech company CeQur has secured fresh equity funding to further drive…
startupticker.ch